GET DAILY SIGNALSBrighthouse Financial (BHF) Q3 2026 Results: Steady Capital Amid Acquisition Delays
Key Takeaways
- Brighthouse Financial reported third quarter 2026 net income available to common shareholders of $302 million, or $5.21 per diluted share, down from $453 million ($7.89 per share) a year earlier.
- Adjusted earnings excluding notable items fell to $213 million ($3.68 per share), below the $261 million ($4.54 per share) recorded in the prior-year quarter.
- Total revenues declined to $853 million from $1.82 billion, pressured by higher net derivative losses.
- Statutory combined total adjusted capital was $4.8 billion, with an estimated combined risk-based capital (RBC) ratio of 415% to 435%, within the company's 400%–450% target range.
- The pending $70.00 per share all-cash merger with Aquarian Capital (valued at roughly $4.1 billion) remains delayed by insurance regulatory approvals, with the outside date extended to December 6, 2026.
- Annuity sales of $2.4 billion fell 12% year over year, while Shield Level Annuity sales stayed strong at $2.1 billion.
- Get more detail on BHF's Major News, Today's Price Move, Price Targets, and Forecasts on Tickeron's dedicated pages.
- Explore Trending AI Robots to discover AI-driven trading strategies.
Why These Results Stand Out Right Now
Brighthouse Financial ranks among the larger U.S. providers of annuities and life insurance. Its third-quarter 2026 numbers land at a distinctive point in time. The firm sits in the midst of a pending all-cash deal with Aquarian Capital, first announced in November 2025 at $70 per share. That backdrop turns this report into a check on capital strength and regulatory momentum as much as on day-to-day operations. I am also watching how the recent rise in interest rates and the annual actuarial review are shaping reserves and the risk-based capital ratio, a central gauge of an insurer’s buffer. In that setting, the quarter gives a useful read on core profitability, investment income patterns, and the capital foundation supporting the merger.
What the Numbers Show
For the third quarter of 2026, BHF posted net income available to common shareholders of $302 million, or $5.21 per diluted share, compared with $453 million ($7.89 per share) in the same stretch a year ago. Total revenues reached $853 million versus $1.82 billion in the prior-year period, reflecting larger net derivative losses. On a non-GAAP basis, adjusted earnings came in at $527 million ($9.12 per share), down from $970 million ($16.87 per share). Stripping out notable items tied to the actuarial review left adjusted earnings at $213 million ($3.68 per share) versus $261 million ($4.54 per share) in the third quarter of 2025. Net investment income totaled $1,257 million, while adjusted net investment income was $1,310 million, producing an adjusted yield of 4.41%. Annuity sales totaled $2.4 billion, off 12% from a year earlier, though Shield Level Annuity sales held firm at $2.1 billion. Statutory combined total adjusted capital stood at $4.8 billion, and the estimated combined RBC ratio landed between 415% and 435%.
Investor Focus and Market Tone
Attention around BHF stays centered on the pending Aquarian Capital transaction more than on the operating details alone. The quarter brought lower net income and adjusted earnings excluding notable items, plus a notable jump in net derivative losses that trimmed headline revenue. At the same time, the capital position stayed inside the targeted band and the RBC ratio remained well above regulatory floors. The key update concerned the merger: the company noted that required insurance regulatory approvals are unlikely before the December 6, 2026 outside date, and the parties are discussing an extension. That open question continues to frame sentiment, and the eventual path of the deal is likely to influence the stock more than earnings variances in the near term. I checked the broader peer comparison using Tickeron’s AI Screener to see how the capital metrics line up with industry norms.
What to Watch Going Forward
The clearest near-term driver remains the merger. Investors will track whether BHF and Aquarian Capital amend the agreement to push the outside date past December 6, 2026, and whether approvals in Delaware, New York, and Massachusetts advance. Any clarity on timing or closing terms would likely set the tone for the shares. Beyond the transaction, the core business deserves attention. Higher interest rates and the rollout of the NAIC’s new Generator of Economic Scenarios framework already lifted reserves this quarter, a pattern that may keep influencing statutory capital and the RBC ratio. Investment income trends also matter: adjusted net investment income rose from the prior quarter on stronger alternative returns but declined year over year due to lower average assets. Sales momentum in Shield Level Annuities continues to stand out even as overall annuity sales eased on softer fixed-annuity demand. How these products hold up in the current rate environment, and whether underwriting margins and expenses stabilize, will shape standalone earnings power irrespective of the deal’s outcome.
AI Tools in My Research Process
When I review quarterly results like these, I often turn to Tickeron’s AI Screener to quickly compare capital ratios, sales trends, and valuation multiples across the insurance sector. The platform lets me apply filters for industry, fundamentals, and recent performance so I can place a single company’s numbers in better context without spending hours on manual screens. It has become a regular part of how I cross-check data points before forming a view.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
BHF sees MACD Histogram crosses below signal line
BHF saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on October 09, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 43 instances where the indicator turned negative. In 29 of the 43 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 67%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BHF as a result. In 60 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 67%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BHF declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 64%.
The Aroon Indicator for BHF entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 10 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 22 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
BHF may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 19 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: BHF's P/B Ratio (0.373) is slightly lower than the industry average of (1.352). P/E Ratio (3.353) is within average values for comparable stocks, (20.493). Projected Growth (PEG Ratio) (0.010) is also within normal values, averaging (0.463). BHF has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.047). P/S Ratio (0.445) is also within normal values, averaging (1.303).
The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. BHF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 88 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 92 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BHF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 60, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of life insurance and retirement income services
Industry LifeHealthInsurance